😺 The ACTUAL ChatGPT 3 moment for robotics (one-shot learning)
The Neuron 1 month ago 10
Merck and Moderna reported a first positive Phase 3 result for an individualized mRNA cancer therapy that uses AI-selected tumor targets. The AI predicts up to 34 neoantigens from a patient’s sequencing data before the therapy is manufactured for that patient. This shifts personalized immunotherapy toward per-patient AI target selection and highlights a related trend in robotics where a model (GEN-1.5) can attempt new tasks from a single 3–12 second physical demonstration.